This study demonstrated that non-glycosylated eG vaccines with or without an adjuvant, induced higher levels of antibodies and better attenuated the Th2 responses and eosinophilia after RSV challenge compared with the glycosylated mG vaccine (results are summarized in Table 1). Here, PODXL2 is linked to Increased total eosinophil count.